A 20-year-old male was admitted with a 6 weeks history of left hemicranial headache, associated with vomiting of 10 days duration. There was history of drooping of left eye lid of 1 week duration. On examination, the left eye had partial ptosis and 6 th nerve palsy. The remaining ophthalmological and neurological examinations were normal, and the past medical history was not significant. Patient was evaluated with computerized tomogram (CT) and magnetic resonance imaging (MRI) brain. The CT scan showed a homogeneous, expansile mass with lytic bone destruction involving the clivus, sphenoid sinus, sella and nasopharynx with homogeneous well enhancement on contrast administration. There was egg shell calcification noted on the bone window. The MRI brain plain study demonstrated the lesion in the clivus and sphenoid sinus, sella which was isointense on the T1 and
Introduction
Giant cell tumor (GCT) of bone constitutes 3-7% of all bone tumors and in those head and neck area including skull comprises of 2%. [1] In the head and neck region, GCT occurs principally in the jaw bones and less commonly in the ethmoidal bones, sphenoid bones, zygomatic bones, temporal bones, and frontal bone. [1] Although rare, skull base GCT involves mostly sphenoid bone followed by petrous temporal bone. [2] The common occurrence in the sphenoid bone is due to the enchondral ossification as compared to membranous ossification of other skull bones. [1] GCT arises from the nonosteogenic stromal cells of bone marrow. [1] We present an interesting report of the GCT arising from the clivus in a 20-year-old male with review of literature. 
Discussion
This tumor is also known as GCT of epiphysis, localized osteitis fibrosa cystica or osteoclastoma. GCT is a solitary lucent lesion with osteoclast-like giant cells and stromal cells. The exact etiology of the GCT is not known but presumed to be due to parathyroid hormone related protein, increased receptor activator of nuclear factor-κB ligand (RANKL) expression by stromal cells of GCT of bone, which in turn causes the resorption of bone. [3] GCT of the clival and sphenoid bone are generally present with the headache, III, IV, VI cranial nerves, visual loss, and proptosis due to involvement of sphenoid bone, sphenoclival junction, and middle cranial fossa. [1, 2] According to Canpanascci et al., GCT is radiologically graded into three grades. associated with a well defined margin and thin rim of mature bone; Grade 2 -tumor is well defined but has no radiopaque rim; Grade 3 -tumor with fuzzy borders. Our case corresponds to grade 2, which has moderate prognosis according to Canpanascci. [4] Histopathologically tumor shows osteoclastic giant cells that contain more than 15 round to oval shaped nuclei per cell, never show mitotic activity and probably formed from fusion of stromal cells. GCT also characteristically contains stromal cells, which have single nucleus, arranged in storiform pattern with 5 to 10 mitoses per high power field, express intracellular adhesion molecule-1. Hemorrhage, hemosiderin and even necrosis may be seen. Upto 50% may have reactive osteoid laid down in trabecular pattern. Immunohistochemistry, though not essential to diagnose, may show positive stain for betacatenin, cyclin D1, MMP -1, MMP -13, CD 34, P53, PDGFA, and C-kit. Recent study has shown that CCAAT/enhancer binding protein beta (C/EBPbeta) is a RANKL promoter activator in stromal cells of GCT of bone and which plays an important role in the osteolytic characteristics and pathological causes of GCT of bone. [5] MMP -13 is a principal proteinase present in GCT and Runx2 may play a crucial role in cytokine-mediated MMP-13 expression in GCT stromal cells. [6] Presence of P53 indicates high risk of local recurrence and metastasis in GCT. [7] Approximately, 84% of GCT show telomeric fusion in various chromosomes like 11p, 13p, 15p, 18p, 19p, and 21p, with telomere length reduction [8] (more in grade 3 than grade 1 and 2), and centromere amplification [9] (higher in recurrent and malignant GCT). Differential diagnoses for GCT are Brown tumor, Osteoblastoma, Aneurysmal bone cyst, Giant cell rich fibrosarcoma and Dedifferentiated chondrosarcoma.
GCT work up should include detailed history, physical examination, serum calcium and phosphate levels, serum parathyroid hormone level, bone scan, chest X-ray, CT, and MRI. Treatment modalities include enbloc resection, curettage, curettage and adjuvant chemotherapy (doxorubicin, cisplatin, methotrexate, zolendronate, and raloxefine) or radiotherapy. [10] Recurrence in long bone GCT is increased in the ascending order with enbloc resection, subtotal resection with adjuvant treatment (chemotherapy or radiotherapy), curettage with PMMA cement and only curettage. [2, 10] Giant cell tumor is associated with soft tissue recurrence and lung metastasis. [11] Due to inadequate availability of literature the definitive treatment for skull base GCT is uncertain. [2] Radiotherapy has vital role as showed in previous case reports of skull base GCT. [2] In one study, unresenctable lesions treated with 57.6 Gy mean dose IMRT for sphenoid lesion and followed for 60 months showed good tumor control and no side effects. [12] There were case reports showing usage of gamma knife radiosurgery for petrous bone GCT. [13] Chemotherapy with adriamycin in previous skull base GCT showed good control in one study. [2] Bisphosphonates may be useful in decreasing local recurrence when compared with placebo (4.2% vs 30%), mechanism appears to be apoptosis of spindle cells in GCT. [14] In vitro studies with zolendronate loaded bone cement [15] and phase 2 trial of Denosumab [16] showed promising results in the control of the GCT, may be useful in future for unresectable tumors. In long bone tumors GCT metastasize to lungs in 1-9%. Malignant transformation of GCT has been reported, mostly due to adjuvant radiotherapy. As radical surgery is difficult unlike other sites, adjuvant treatment has pivotal role. [18] Previously reported cases were tabulated in Table 1 .
Conclusions
GCT involving the skull base is rare. Sphenoid bone is the most common bone involved followed by petrous temporal bone. As radical surgery is difficult unlike other sites, adjuvant treatment has pivotal role. Radiation therapy with IMRT, stereotactic radiosurgery, and chemotherapy with adriamycin is useful. Bisphosphonates may have a role in the control of local recurrence.
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